Well, FMK, it does appear that there will be a looming disparity in our collective ability to give informed opinions with respect to
Valence's patents as opposed to, say, financing, of which I thought the group gave a good accounting(no pun). There just isn't enough
technical expertise and it would be a can of worms with no balanced conclusions in sight. There are only a few people in the country who could survey all these and adjudge the merit, timeliness,
legalities , competitiveness, cost effectiveness, and on and on. Moreover, of the people who could do this, I would guess about two thirds of them work for Valence. From where we stand, inferential data
are going to be our main guideposts. Insider buying and a host of other examples point to a positive outcome. There are negatives, mainly the lack of guarantees, but if such were given, the stock would already be out of our price range. I strongly urge the threadsters to
avoid this course of discussion. I do believe , without belittling what has been offered so far, that attempts to pontificate on this
esoteric subject will be a fool's errand. |
